CMS rolls out RAPID coverage program to accelerate access to breakthrough medical devices
CMS and FDA are launching RAPID, a program aimed at speeding Medicare coverage for breakthrough devices. The idea is to reduce the delay between approval and real-world use, a gap that has long frustrated innovators and patients alike. If successful, RAPID could become a template for broader reimbursement reform in medtech.
RAPID is the federal government’s latest attempt to fix the reimbursement bottleneck that so often slows medtech adoption. The new pathway is intended to help breakthrough devices move from regulatory clearance to Medicare coverage faster, addressing a long-standing mismatch between innovation timelines and coverage timelines.
That matters because reimbursement uncertainty can be as damaging as regulatory rejection. For device developers, delayed coverage can depress valuations, scare off investors, and make launch planning nearly impossible. For providers, it can create hesitation around adopting promising technologies even after they are cleared for use.
The policy also hints at a more pragmatic federal stance toward innovation. Rather than treating approval and coverage as separate worlds, CMS and FDA are trying to coordinate them more closely. That could be particularly useful in areas where device benefits are substantial but evidence evolves quickly after launch.
The downside is obvious: faster coverage may mean earlier payment decisions based on less complete data. CMS will need strong guardrails to ensure the program does not simply accelerate uncertainty. Still, RAPID suggests the U.S. may finally be building a reimbursement system that is more compatible with the pace of modern device development.